In lung cancer, mutant Kras is known to drive IL-8 release from cancer cells via activation of the AP-1 and NF-κB transcription pathways; IL-8 in the TME drives M2 macrophage polarization and neutrophil recruitment to promote progression (Wislez et al., 2006). This evidence concerns the gene KRAS and lung carcinoma.